Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease – Biogen | Investor Relations

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease – Biogen | Investor Relations

Source link : https://news.google.com/rss/articles/CBMiwwFBVV95cUxOTFoybVdCSUNlU0toN0VwYm5JUnNtTW5xdlVELXFmczMzNUdBYUNSb2t3cGE1azhldzBFN3JacmRlQkxTUmxGaWswQjZCa0tHYm1nbFdxQ0dLRlYxNXBQNk9WV3BqUE1ISHI3NnFyTnZEVThRMWxRS0IySlBvd05aLWh0cENPdnBQaGNZR3lwUnpXRzA2VTZwV19EQnpucEU4VFVHQ0U3VDh2dnBsLVZTWkVta1pyUXBSY1BNWDF1YWtwWEU?oc=5

Author :

Publish date : 2024-11-14 16:26:00

Copyright for syndicated content belongs to the linked Source.

Exit mobile version